Northwire Canada EditionFriday, July 10, 2026
Sign inSubscribe
Northwire
⌕
FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9% FCI 0.400 −9.1% GR 0.075 +0.0% AII 22.38 +7.6% TUNG 1.72 +1.8% LGO 1.01 −2.4% EMM 0.080 +0.0% OGN 3.45 +2.1% MSA 6.30 −2.0% SGZ 0.045 +0.0% S 0.135 +12.5% GRSL 0.310 −3.1% DEX 0.390 +1.3% WMS 0.040 +0.0% EMPR 0.840 +2.4% SAGA 0.480 +0.0% ABX 51.73 −0.9%
Other Routine +

Aptose Presents Safety, Response, and MRD Clinical Data from TUSCANY Phase 1/2 Clinical Trial of Tuspetinib Triplet Therapy in Newly Diagnosed AML at the 2026 EHA Congress in Oral Presentation

Clinical data validates tuspetinib's AML potential, but acquisition hinges on delayed Korean regulatory approval.

By The Northwire Desk — AI Analysis Jun 15, 2026 · 07:30 APS · 2.19 APTOSE BIOSCIENCES INC.
Executive Summary
  • Aptose Biosciences presented updated Phase 1/2 TUSCANY trial data at the 2026 EHA Congress on June 15, 2026.
  • The tuspetinib (TUS) + venetoclax + azacitidine triplet demonstrated an 86.2% composite complete response (CRc) rate across 29 evaluable patients.
  • Minimal residual disease (MRD) negativity was achieved in 86.4% of responders and 62.5% of all dosed patients.
  • Notable efficacy in adverse genetic profiles: 100% CRc in all four TP53-mutated patients with complex karyotypes at the 160 mg dose.
  • Safety profile remains favorable: no treatment-related deaths, no QTc prolongation, CPK elevations, or differentiation syndrome.
  • The announcement coincides with a routine update on the Hanmi Pharmaceutical acquisition, which has been delayed to June 2026 due to pending Korean regulatory approvals.
  • Clinical data is consistent with prior presentations at ASH 2025 (90% CRc) and ESH 2025 (90% CRc), reflecting incremental cohort expansion rather than a paradigm shift.
Material Impact
  • The clinical update reinforces the existing investment thesis but does not introduce fundamentally new information. The response rates and safety profile align with prior expectations set by management.
  • The M&A timeline shift to June is standard for cross-border regulatory reviews. While it extends the arbitrage window, it does not alter the transaction economics (C$2.41 per share).
  • Financially, the company remains in a cash-burn phase with a Q1 2026 net loss of $7.6M and only $4.1M in cash. Operations are entirely dependent on uncommitted advances from Hanmi.
  • The stock is trading in a tight arbitrage range near the acquisition price. Positive clinical data provides fundamental validation but is unlikely to drive a significant standalone re-rating given the imminent deal closure.
APS · Price
Company Overview
  • Aptose Biosciences is a clinical-stage biotechnology company focused on precision oncology therapies.
  • Lead asset: Tuspetinib (TUS), a multi-targeted inhibitor of growth factor signaling pathways.
  • Primary indication: Newly diagnosed acute myeloid leukemia (AML) patients ineligible for intensive induction chemotherapy.
  • Clinical strategy: Evaluating TUS in combination with standard-of-care venetoclax and azacitidine (TUSCANY Phase 1/2 trial).
  • Corporate action: Being acquired by Hanmi Pharmaceutical Co. Ltd. (South Korea) via a statutory plan of arrangement for C$2.41 per share in cash.
  • Secondary programs: Luxeptinib development has been wound down and license rights returned to CrystalGenomics Invites.
Read the original news release →

More from APTOSE BIOSCIENCES INC.

Jun 30, 2026 · 19:32

Aptose Biosciences Closes $6.1M Hanmi Takeover, Delisting TSX as Clinical-Stage AML Biotech Exits Public Markets

M&A / Property May 29, 2026 · 07:30

Aptose Deal Closing Delayed to June; Hanmi Funding Secures Runway Amidst Regulatory Hurdles

Financings May 13, 2026 · 17:00

Hanmi Acquisition Delayed to May 2026 as Aptose Burns Cash Faster Than Expected

Earnings Apr 30, 2026 · 07:30

Hanmi Acquisition Closing Delayed to May as Korean Regulatory Review Continues

M&A / Property Mar 31, 2026 · 17:22

Aptose Shareholders Approve C$2.41 Hanmi Buyout as Clinical Data Validates Triplet Strategy

Earnings Mar 23, 2026 · 17:17

Aptose Bio gets Glass, Lewis support for takeover

M&A / Property